Claims for Patent: 11,078,485

Summary for Patent: 11,078,485

Title:	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Abstract:	The present invention provides compositions comprising at least one oligomeric compound comprising an alternating motif and further include a region that is complementary to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression.
Inventor(s):	Charles Allerson, Balkrishen Bhat, Anne B. Eldrup, Muthiah Manoharan, Richard H. Griffey, Brenda F. Baker, Eric E. Swayze
Assignee:	Ionis Pharmaceuticals Inc
Application Number:	US16/286,075
Patent Claims:	1. A composition comprising a first oligomeric compound and a second oligomeric compound, wherein: said first oligomeric compound is capable of hybridizing with said second oligomeric compound; said first oligomeric compound is complementary to and capable of hybridizing to a selected nucleic acid target; each of said first and said second oligomeric compounds independently comprises 20-23 linked nucleosides; at least one of said first and said second oligomeric compounds comprises a region having the formula X1-Y-X2, wherein Y is a region of from about 5 to about 12 linked nucleosides and each of X1 and X2 is, independently, a plurality of linked nucleosides having the formula FSFS, where one of F and S is a 2′-F modified nucleoside and the other of F and S is a 2′-O-CH3 modified nucleoside; and each internucleoside linkage of said first and said second oligomeric compound is, independently, a phosphodiester or a phosphorothioate internucleoside linkage. 2. The composition of claim 1 wherein said first oligomeric compound comprises a 5′-phosphate group. 3. The composition of claim 1 wherein said second oligomeric compound comprises a 5′-phosphate group. 4. The composition of claim 1 wherein each of said first and said second oligomeric compounds comprise a 5′-phosphate group. 5. The composition of claim 1 wherein at least one of said first and said second oligomeric compounds comprises at least one conjugate group. 6. The composition of claim 1 wherein at least one of said first and said second oligomeric compounds comprises at least one terminal cap moiety attached at the 3′-end, the 5′-end or both the 3′-end and the 5′-end of the oligomeric compound. 7. A method of inhibiting gene expression comprising contacting one or more cells, a tissue or an animal with a composition of claim 1.